Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for October 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during October 2014.

For an indepth analysis of these deals, read 'Pharma deals during October 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Becton Dickinson/CareFusion
Company acquisition
Medical equipment builds US sales base
12,200
Auxilium/Endo
Company acquisition
Urology and orthopaedic products including alprostadil for ED
2,600
NewLink Genetics/Genentech
Collaboration and licence
For development of NLG919 and next generation IDO pathway inhibitors
1,150
Sutro Biopharma/Celgene
Licence plus option to acquire Sutro
For development of multispecific antibodies and antibody drug conjugates (ADCs)
1,000
Aduro BioTech/J&JExpansion of collaboration
Lung cancer immunotherapies including ADU 214
847
Lineage Therapeutics/Impax LaboratoriesCompany acquisition
Includes generic and branded products such albendazole and epinephrine
700
Actavis/Durata Therapeutics
Merger with Actavis subsidiary
Brings Dalvance a recently approved  novel antibiotic for acute skin structure infections
675
Acorda Therapeutics/Civitas Therapeutics
Company acquisition
Includes CVT 301 in P3 for Parkinson's as well as pulmonary delivery technology
525
F-star Alpha/BMS
Option to acquire F-star Alpha
Includes FS102 a P1 ready treatment for HER2 positive patients with breast /    gastric cancer
475
CureTech/Medivation
Exclusive global licence
For pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody
335
Forendo Pharma/Apricus Biosciences
Licence [A]
Fispemifene a selective oestrogen modulator in P2 for secondary hypogonadism
318
Novartis/CSL
Asset purchase
Influenza vaccines
275
Five Prime/GSK
Expansion of collaboration
Identifying new agents in asthma and COPD
196
Bavarian Nordic/J&J
Licence and supply
For multivalent MVA-BN Filovirus vaccine
187
Lexicon Pharmaceuticals/Ipsen
Licence [B]
Telotristat etiprate in P3 for carcinoid syndrome
145
Brabant Pharma/Zogenix
Acquisition

Includes fenfluramine for orphan I indication of Dravet syndrome
130
TesoRx Pharma/Aspen
Licence [C]
For TSX 002 an unmodified oral   testosterone replacement
95
Oxford BioMedica/Novartis
Expansion of collaboration
Lentiviral vectors expressing CTL019 CAR-T therapy for leukaemia
90
Heidelberg Pharma/Roche
Licence with options to targets
Development of ADCs based on coupling α-amantin to antibodies
66

All deals are worldwide unless otherwise noted.

A: US only
B: Outside N America and Japan
C: Excluding US EU Japan, China and the Middle East

The Deal Watch table is compiled by Medius Associates

10th November 2014

The Deal Watch table is compiled by Medius Associates

10th November 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Infographics